Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 3/20 | 0.64 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.59 |
| ▸ | GUSB | P08236 | 1/20 | 0.58 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.52 |
| ▸ | MAP1LC3A | Q9H492 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13199109 | 0.89 | PLAU (0.61) | NR4A2GUSBNR1H4MAOBPTPN1 | |
| SCHEMBL13199215 | 0.88 | HPGD (0.65) | SMPD1NR1H4MEN1KMT2AHPGD | |
| SCHEMBL13199231 | 0.86 | TDP1 (0.62) | MEN1KMT2A | |
| SCHEMBL13199236 | 0.85 | ALDH1A1 (0.66) | MEN1KMT2A | |
| SCHEMBL13199129 | 0.84 | ALDH1A1 (0.57) | MEN1KMT2A | |
| SCHEMBL21612769 | 0.84 | SMPD1 (0.69) | SMPD1NR4A2GUSBNR1H4MAOB | |
| SCHEMBL13199228 | 0.82 | NLRP3 (0.53) | — | |
| SCHEMBL2951993 | 0.82 | SMPD1 (0.44) | SMPD1NR4A2MEN1KMT2A | |
| SCHEMBL13199130 | 0.81 | MEN1 (0.60) | SMPD1NR4A2MAOBMEN1KMT2A | |
| SCHEMBL2951792 | 0.81 | MAOB (0.50) | SMPD1NR4A2MAOBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767716-B2 | Acyl hydrazines as kinase inhibitors, in particular for SGK | MERCK PATENT GMBH (DE) | 2010-08-03 | — | — | US | disclosed |
| US-7767716-B2 | Acyl hydrazines as kinase inhibitors, in particular for SGK | MERCK PATENT GMBH (DE) | 2010-08-03 | — | — | US | disclosed |
| EP-1866280-B1 | ACYL HYDRAZIDES AS KINASE INHIBITORS, IN PARTICULAR FOR SGK | MERCK PATENT GMBH (DE) | 2008-08-13 | — | — | EP | disclosed |
| US-20080167380-A1 | Acyl Hydrazines as Kinase Inhibitors, in Particular for Sgk | MERCK PATENT GMBH (DE) | 2008-07-10 | — | — | US | disclosed |
| US-20080167380-A1 | Acyl Hydrazines as Kinase Inhibitors, in Particular for Sgk | MERCK PATENT GMBH (DE) | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167380-A1 | Acyl Hydrazines as Kinase Inhibitors, in Particular for Sgk | SGK1, AGK, SGK2 | SMPD1 1400/4885NR4A2 2714/4885GUSB 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.